Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer	Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder	Recruiting	Not applicable	2026-04-29		NCT07095023

10 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Affiliated Cancer Hospital of Shantou University Medical College	13
Cancer Hospital of Guangxi Medical University	22
First Affiliated Hospital of Wenzhou Medical University	117
Guangdong Women and Children Hospital	8
Hainan People's Hospital	12
Nanfang Hospital, Southern Medical University	248
Peking University Cancer Hospital & Institute	189
Peking University Shenzhen Hospital	48
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	285
The Affiliated Hospital Of Guizhou Medical University	33

9 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Cancer Hospital of Shantou University Medical College	Shantou	China	9
Guangdong Women and Children Hospital	Guangzhou	China	3
Guangxi Provincial Cancer Hospital	Nanning	China	1
Hainan Central Hospital	Haikou	China	1
Peking University Cancer Hospital	Beijing	China	11
Peking University Shenzhen Hospita	Shenzhen	China	1
Sun Yat-sen Memorial Hospital	Guangzhou	China	16
the Affiliated Hospital of Guizhou Medical University	Guiyang	China	29
The First Affiliated Hospital of Wenzhou Medical University	Wenzhou	China	41